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Abstract To identify protein components of the intestinal
cholesterol transporter, rabbit small intestinal brush border
membrane vesicles were submitted to photoaffinity labeling using
photoreactive derivatives of 2-azetidinone cholesterol absorption
inhibitors. An integral membrane protein of Mr 145.3 þ 7.5 kDa
was specifically labeled in brush border membrane vesicles from
rabbit jejunum and ileum. Its labeling was concentration-
dependently inhibited by the presence of cholesterol absorption
inhibitors whereas bile acids, D-glucose, fatty acids or cephalexin
had no effect. The inhibitory potency of 2-azetidinones to inhibit
photolabeling of the 145 kDa protein correlated with their in vivo
activity to inhibit intestinal cholesterol absorption. These results
suggest that an integral membrane protein of Mr 145 kDa is (a
component of) the cholesterol absorption system in the brush
border membrane of small intestinal enterocytes. ß 2000 Fed-
eration of European Biochemical Societies. Published by Else-
vier Science B.V. All rights reserved.
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1. Introduction
Intestinal absorption of cholesterol is a major determinant
for body cholesterol homeostasis and speci¢c inhibitors of
intestinal cholesterol absorption may become major drugs of
the future to prevent atherosclerosis and cardiovascular dis-
eases. The molecular mechanism responsible for intestinal
cholesterol absorption is poorly understood and discussed
controversially [1^3]. Originally a passive process was as-
sumed [4] but several ¢ndings support the involvement of a
protein-mediated speci¢c process: (i) Cholesterol but not
closely related plant sterols like L-sitosterol or campesterol
are absorbed by the small intestine [5]. (ii) Cholesterol trans-
port from mixed micelles to intestinal brush border membrane
vesicles (BBMV) is protease-sensitive [6]. (iii) Highly potent
compounds of di¡erent chemical structures have been identi-
¢ed as speci¢c inhibitors of intestinal cholesterol absorption
[7^15]. Hauser and co-workers have suggested an intestinal
cholesterol transporter based on their in vitro studies with
intestinal BBMV [6,16,17] and several proteins have been de-
scribed in the past as possible components of intestinal cho-
lesterol absorption [16^18]. Their role, however, for intestinal
cholesterol absorption is still far from clear and remains to be
elucidated. The ¢rst step of intestinal cholesterol absorption is
the interaction of cholesterol with the brush border membrane
of small intestinal enterocytes. Recent studies have demon-
strated a speci¢c binding of cholesterol absorption inhibitors
to the brush border membrane of enterocytes in duodenum,
jejunum and ileum [12,19]. We therefore attempted to identify
the respective binding protein(s) for cholesterol absorption
inhibitors by photoa⁄nity labeling with photoreactive ana-
logues of 2-azetidinone-derived cholesterol absorption inhibi-
tors. In the present manuscript we describe the ¢rst molecular
identi¢cation of speci¢c binding proteins for cholesterol ab-
sorption inhibitors which are probably involved in intestinal
cholesterol absorption. An integral membrane protein of Mr
145 kDa in the enterocyte brush border membrane exerts the
characteristics of the hitherto unknown intestinal cholesterol
transporter.
2. Materials and methods
2.1. Materials
The cholesterol absorption inhibitors shown in Fig. 1 were synthe-
sized at Aventis Pharma Deutschland GmbH according to published
procedures [7^9]. The photoreactive analogues C-1 and C-2 were syn-
thesized by acylation of aminobenzyl derivatives at R4 with 4-azi-
do[3,5-3H]benzoyl-N-hydroxysuccinimide ester (NEN Du Pont de
Nemours) or [3H]acetanhydride leading to radiolabeled C-1 and C-2
with speci¢c radioactivities of 45.7 and 3.41 Ci/mmol, respectively.
Photoreactive bile acid derivatives carrying a diazirino function at
position 3 or 7 were synthesized as described [20,21]. Acrylamide,
N,NP-bismethylenacrylamide, materials for electrophoresis and marker
proteins for the determination of molecular masses were purchased
from Serva (Heidelberg, Germany) or Sigma (Mu«nchen, Germany).
Scintillators (Quickszint 501 and 361) and the tissue solubilizer Bio-
lute S were from Zinsser Analytic GmbH (Frankfurt, Germany). Pro-
tein was determined with a Bradford assay kit from Bio-Rad (Mu«n-
chen, Germany).
2.2. Animals
Male New Zealand white rabbits weighing 4^5 kg (Harlan Winkel-
mann, Borchen, Germany) were kept on Altromin0 standard diet C
2023 (Altromin0, Lage, Germany) ad libitum. For cholesterol chal-
lenge the animals obtained Altromin0 standard diet C 2023 enriched
with 3% (w/w) cocoa fat and 0.2% (w/w) cholesterol ad libitum for a
period of 10 days. Animals were kept at 18^20‡C on a 12 h dark/light
rhythm. Rabbit intestinal BBMV from jejunum and ileum were pre-
pared by the Mg2 precipitation procedure and characterized as de-
scribed earlier [22].
2.3. Inhibition of cholesterol absorption
Intestinal cholesterol absorption was determined by a modi¢cation
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of the method of Zilversmit and Hughes [23]. Male NMRI mice
(Charles River Deutschland GmbH, Sulzfeld, Germany) kept on reg-
ular chow (Altromin0, Lage, Germany) were starved for 12 h. 0.5 ml
of a solution of 0.5% methylcellulose/5% Solutol (BASF, Ludwigsha-
fen, Germany) as vehicle with or without 3 mg of the respective
cholesterol absorption inhibitor were applied by gavage to each ani-
mal followed by 0.25 ml of Intralipid0 (Pharmacia and Upjohn, Er-
langen, Germany) solution containing 0.24 WCi [14C]cholesterol and
0.25 WCi [3H]sitostanol. The animals (¢ve mice per group) were kept
on metabolism cages and feces were collected. After 24 h the animals
were killed and the radioactivity in the feces and the liver was deter-
mined by combustion analysis.
2.4. Photoa⁄nity labeling and binding studies
Photoa⁄nity labeling was carried out in a Rayonet RPR-100 pho-
tochemical reactor (The Southern Ultraviolet Company, Hamden,
CT, USA) equipped with four RPR 2537 Aî lamps. BBMV (100^200
Wg of protein) were incubated at 20‡C for 5 min in the dark with the
appropriate concentrations of C-1 or C-2 in a total volume of 200 Wl
in 10 mM Tris/HEPES bu¡er (pH 7.4)/100 mM NaCl/100 mM man-
nitol followed by irradiation at 254 nm for 20 s (C-1) or 60 s (C-2).
Subsequent to photoa⁄nity labeling, BBMV were washed twice with
the above bu¡er, proteins were precipitated and analyzed by SDS^gel
electrophoresis [22]. For Western blotting, proteins were transferred
to nitrocellulose membranes (0.2 Wm trans-blot transfer medium from
Bio-Rad) from SDS^gels in a trans-blot cell (Bio-Rad) with 25 mM
Tris/192 mM glycine (pH 8.3)/33% (v/v) methanol. Blotting was per-
formed of 300 mM for 3 h followed by 400 mAî for 0.5 h. Immuno-
detection was performed with antibodies against the scavenger recep-
tor SR-BI (Novus, Cambridge, UK) or the C-terminus of the rabbit
ileal Na/bile acid cotransporter [24] by using the Western light chem-
iluminescence detection system from Serva (Heidelberg, Germany).
Radioactively labeled polypeptides were detected either by liquid scin-
tillation counting after slicing of the gels into 2 mm pieces and hy-
drolysis of proteins with 0.25 ml of tissue solubilizer Biolute S or by
£uorography [22]. Binding of radiolabeled C-1 and C-2 to rabbit small
intestinal BBMV was determined by incubation of BBMV with C-1 or
C-2 in the concentration range 1 nM to 10 WM in the absence or
presence of 1^50 WM competing ligands for 60 min at 20‡C followed
by centrifugation and measurement of membrane-associated radioac-
tivity by liquid scintillation counting.
3. Results
3.1. Rationale for the design of photoreactive cholesterol
absorption inhibitors
Binding proteins for photoreactive analogues of 2-azetidi-
none-derived cholesterol transport inhibitors (Fig. 1) in
BBMV from small intestinal cells probably are speci¢c com-
ponents of the uptake machinery for cholesterol across the
enterocyte brush border membrane for the following reasons:
1. 2-Azetidinones are speci¢c inhibitors of intestinal choles-
terol absorption [7^12] in di¡erent animal species including
rabbits [25] and humans [26].
2. 2-Azetidinone- as well as sterol glycoside-derived cholester-
ol transport inhibitors act at the brush border membrane
of enterocytes from duodenum, jejunum or ileum blocking
the movement of cholesterol into villi of enterocytes [19].
3. The in vivo potency of cholesterol transport inhibitors cor-
relates with their binding a⁄nity to enterocyte brush bor-
ders [27].
4. 2-Azetidinone-derived cholesterol transport inhibitors
show clear structure^activity relationships [7^9,27] indicat-
ing a speci¢c interaction with protein components.
Structural changes in position R4 of 2-azetidinones are well
tolerated and small residues of R4 completely retain pharma-
cological activity as cholesterol absorption inhibitors [9]. We
therefore introduced radiolabeled photoreactive groups into
position R4 obtaining with C-1 a nitrene-generating azido
derivative whereas the [3H]acetyl-aminobenzyl derivative C-2
should be suited for direct photoa⁄nity labeling [28]. The
Fig. 1. Chemical structure of 2-azetidinone cholesterol absorption
inhibitors.
Fig. 2. Photoa⁄nity labeling of rabbit small intestinal BBMV with
photoreactive cholesterol absorption inhibitors. BBMV isolated
from rabbit ileum (200 Wg of protein, 2 mg/ml) were photolabeled
with 0.212 WM [3H]C-1 or 2.93 WM [3H]C-2 as described in Section
2. Labeled membrane proteins were analyzed by SDS^gel electro-
phoresis on 7.5% gels followed either by £uorography or by slicing
of the gel lanes into 2 mm pieces and detection of radioactivity by
liquid scintillation counting of hydrolyzed proteins. a: After labeling
with [3H]C-1. Top: Fluorographic detection of radioactivity. Bot-
tom: Detection by slicing of the gel and liquid scintillation count-
ing. b: After labeling with [3H]C-2.
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high potency of 2-azetidinone cholesterol reabsorption inhib-
itors such as SCH 58235 with an ED50 value of 0.0005 mg/kg
in the rhesus monkey [11] suggests a low abundance of the
cholesterol transporter in BBMV. Consequently, the photo-
a⁄nity probes C-1 and C-2 were synthesized with high speci¢c
radioactivities of 45.7 and 3.41 Ci/mmol, respectively. The
suitability of radiolabeled C-1 and C-2 as photoa⁄nity probes
was demonstrated by covalent crosslinking to albumin upon
UV irradiation at 254 nm (data not shown). Incubation of
BBMV with radiolabeled C-1 or C-2 demonstrated the meta-
bolic stability of the photoprobes indicating that photoa⁄nity
labeling of small intestinal BBMV with these derivatives
should allow the identi¢cation of the protein(s) responsible
for intestinal cholesterol absorption.
3.2. Photoa⁄nity labeling of rabbit small intestinal BBMV
with radiolabeled cholesterol absorption inhibitors
[3H]C-1 and [3H]C-2
Photoa⁄nity labeling of BBMV from rabbit jejunum or
ileum with C-1 led to a labeling of membrane proteins of
Mr 145.3 þ 7.5, 98.5 þ 1.6, 79 þ 1.4, 61.8 þ 2.5, 55.5 þ 1.4, 46,
41.4 þ 1.3 and 35.2 þ 2.2 kDa (n = 6), the 145 kDa protein
being mostly labeled (Fig. 2). C-2 resulted in a similar labeling
pattern with a prominent labeling of the 145 and 41 kDa
proteins. Variation of the incubation time up to 60 min or
photoa⁄nity labeling in the frozen state did not signi¢cantly
change the labeling pattern. The scavenger receptor SR-BI has
been suggested as a receptor mediating absorption of dietary
cholesterol in the intestine [16]. None of the photolabeled
binding proteins, however, comigrated with SR-BI after im-
munostaining with SR-BI antibodies nor could be precipitated
by SR-BI antibodies excluding the possibility that SR-BI is
the target protein for cholesterol absorption inhibitors. The
molecular weights and described functions make the involve-
ment of other members of the scavenger receptor family in
intestinal cholesterol absorption unlikely [29]. Additionally,
none of the radiolabeled bands showed immunoreactivity
with the ileal Na-dependent ileal bile acid transporter [24].
The labeling of the 62, 56, 46 and 41 kDa was dependent on
the vesicle preparation. Solubilization experiments with non-
ionic or zwitterionic detergents and sodium carbonate identi-
¢ed the labeled proteins of Mr 145, 98, 56 and 35 kDa as
integral membrane proteins. Identical labeling patterns were
obtained with vesicles from rabbit jejunum and rabbit ileum
with a slightly higher labeling of the 145 kDa protein in the
ileum. The identi¢cation of identical binding proteins for cho-
lesterol absorption inhibitors in the jejunum and the ileum is
in line with the ¢ndings that the entire small intestine has the
capacity to absorb cholesterol [30^32].
3.3. Speci¢city of the binding proteins for cholesterol
absorption inhibitors
To identify the prime candidate for the intestinal cholesterol
transporter, di¡erential photolabeling experiments were per-
formed with high and low a⁄nity inhibitors for intestinal
cholesterol absorption. A di¡erence in their in vivo potency
should be re£ected in a di¡erent extent of inhibition on photo-
a⁄nity labeling of the speci¢c binding protein(s). S 3302 is the
racemate of the cholesterol absorption inhibitor SCH 48461
potently inhibiting intestinal cholesterol absorption in rabbits,
Fig. 3. E¡ect of cholesterol absorption inhibitors on photoa⁄nity labeling of rabbit small intestinal BBMV by the photoreactive cholesterol ab-
sorption inhibitor [3H]C-1. BBMV obtained from rabbit ileum (200 Wg of protein, 2 mg/ml) were photolabeled with 0.212 WM [3H]C-1 in the
absence or presence of the indicated concentrations of the cholesterol absorption inhibitors S 6503 or S 3302 followed by SDS^gel electrophore-
sis and detection of radioactivity by liquid scintillation counting. A: Labeling in the presence of S 6503. B: Labeling in the presence of S 3302.
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hamsters, dogs, rhesus monkeys and humans [25,26]. Intro-
duction of a (3S)-hydroxy group in position R2 signi¢cantly
increases the e⁄cacy of 2-azetidinones [8] explaining the high-
er in vivo potency of SCH 58235 compared to SCH 48461
[8,11,12]. In vivo studies with NMRI mice revealed the higher
in vivo e⁄cacy of the (3S)-hydroxy group containing com-
pounds S 6503 ^ a R3-methoxy derivative of SCH 58235 ^
and photoprobe C-2 compared to S 3302. Table 1 shows that
the intestinal absorption of [14C]cholesterol as measured by an
increase in fecal excretion of [14C]cholesterol was strongly in-
hibited by S 6503 and C-2 and moderately by S 3302. In
contrast, fecal excretion of [3H]sitostanol was not signi¢cantly
a¡ected indicating their speci¢c e¡ect on intestinal cholesterol
absorption only. The radioactivity found in the livers 24 h
after application as a measure for intestinal absorption of
[14C]cholesterol was accordingly strongly inhibited by S 6503
and C-2 and weakly by S 3302.
Photoa⁄nity labeling in the presence of increasing concen-
trations of S 6503 and S 3302 led to a speci¢c inhibition in the
extent of labeling of the 145 kDa protein whereas labeling of
the other proteins was not signi¢cantly changed (Fig. 3). Un-
speci¢c e¡ects by optical shielding can be ruled out due to the
comparable extinction coe⁄cients of both compounds. S 6503
was in accordance with its higher in vivo activity more potent
compared to S 3302 to inhibit photolabeling of the 145 kDa
protein. By repeated experiments with di¡erent vesicle prepa-
rations and detection of radioactivity by liquid scintillation
counting and £uorography, IC50 values of 71 þ 18 WM for S
6503 and 129 þ 11 WM for S 3302 (n = 4) were determined.
Fluorographic detection revealed that the labeling of the Mr
62 and 56 kDa were also inhibited by the presence of 2-aze-
tidinones. At present it remains unclear whether these poly-
peptides are closely associated to the 145 kDa protein or
whether the 145 kDa protein is a dimer of the 56/62 kDa
proteins similar to the dimerization of the ileal Na/bile
acid cotransporter [24]. None of the azetidinone-derived cho-
lesterol absorption inhibitors had any in£uence on the intes-
tinal transporters for bile acids, glucose, oligopeptides, alanine
or fatty acids nor on photoa⁄nity of the ileal Na/bile acid
cotransporter [22,24]. Vice versa, none of the substrates for
these transporters in£uenced photoa⁄nity labeling of the 145
kDa protein by C-1 or C-2. In an in vitro binding assay mea-
suring the e¡ect of substrates on the binding of radiolabeled
C-2 to intestinal BBMV, S 6503 was more potent compared to
S 3302 to inhibit binding of radiolabeled C-1 or C-2 to
BBMV, whereas bile acids, glucose, L-lactam antibiotics or
fatty acids had no e¡ect.
3.4. E¡ect of cholesterol feeding on photoa⁄nity labeling of
rabbit small intestinal BBMV by photoreactive cholesterol
absorption inhibitors
Repa et al. [33] demonstrated that intestinal cholesterol
absorption is decreased concomitantly with an increase in
the expression of the ABC-1 transporter protein which pumps
cholesterol out of the enterocyte. The interrelationship of
ABC-1 with the uptake system for cholesterol is unknown.
We therefore investigated whether cholesterol feeding had
an in£uence on photoa⁄nity labeling of BBMV with choles-
terol absorption inhibitors. Rabbits are prone to the develop-
ment of profound atherosclerosis and severe hyperlipidemia
by cholesterol feeding [34]. Preliminary studies showed that
photoa⁄nity labeling of BBMV obtained from rabbits
(n = 3) treated for 10 days with a high cholesterol diet revealed
a slightly higher labeling of the 145 kDa protein compared to
BBMV from rabbits fed with regular chow (Fig. 4).
4. Discussion
Intestinal absorption of cholesterol is a major regulator of
serum cholesterol levels and body cholesterol homeostasis.
Under normal conditions 50^70% of cholesterol is absorbed
by the small intestine, the absorption rate greatly varying
Fig. 4. In£uence of cholesterol feeding on photoa⁄nity labeling of
rabbit small intestinal BBMV by the photoreactive cholesterol ab-
sorption inhibitor [3H]C-2. BBMV (200 Wg of protein, 2 mg/ml) iso-
lated from rabbits kept for 10 days on a standard diet (a) or a high
cholesterol diet (b) were photolabeled with 2.93 WM [3H]C-2 fol-
lowed by SDS^gel electrophoresis and detection of radioactivity by
liquid scintillation counting.
Table 1
E¡ect of 2-azetidinone cholesterol absorption inhibitors on cholesterol absorption in NMRI mice
Control 3 mg S 6503/mouse 3 mg S 3302/mouse 3 mg C-2/mouse
Fecal excretion of [14C]cholesterol 0.23 WCi 0.60 WCi (+160.8%) 0.33 WCi (+43.5%) 0.59 WCi (+156.5%)
Fecal excretion of [3H]sitostanol 0.77 WCi 0.68 WCi (311.6%) 0.75 WCi (32.6%) 0.72 WCi (36.5%)
Retention of [14C]cholesterol in the liver 0.163 WCi 0.047 WCi (371.2%) 0.151 WCi (37.4%) 0.063 WCi (361.3%)
Male NMRI mice (¢ve animals per group) were dosed 0.5 ml of a solution of 0.5% methylcellulose/5% Solutol0 without or with 3 mg of cho-
lesterol absorption inhibitor by gavage followed by 0.25 ml of Intralipid0 solution containing 0.24 WCi [14C]cholesterol and 0.25 WCi
[3H]sitostanol. After 24 h the amount of radioactivity excreted with the feces and retained in the liver was determined. The values represent the
summarized radioactivity of the ¢ve animals per treatment group. For each group two independent determinations of radioactivity in feces or
liver were performed.
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between 29 and 80%. Since the molecular mechanism of in-
testinal cholesterol absorption is unknown, a rational design
of optimized cholesterol absorption inhibitors is not possible
yet. Owing to the ubiquitous distribution of cholesterol in
biological membranes and its physicochemical properties
to incorporate into the lipid bilayer of biological membranes,
photoa⁄nity labeling approaches with photoreactive cho-
lesterol analogues probably will lead to unspeci¢c intra-
membrane labeling of many membrane proteins making an
unequivocal identi¢cation of the putative cholesterol trans-
porter di⁄cult and unlikely. Therefore we made use of the
speci¢city of 2-azetidinones to inhibit intestinal cholesterol
absorption and identi¢ed speci¢c binding proteins for choles-
terol absorption inhibitors by photoa⁄nity in small intestinal
BBMV by photoa⁄nity labeling. An integral membrane pro-
tein of Mr 145 kDa exerts the characteristics for an intestinal
cholesterol transporter:
1. Photoa⁄nity labeling of the integral membrane protein of
Mr 145 kDa was concentration-dependently inhibited by
unlabeled 2-azetidinone cholesterol absorption inhibitors.
2. The inhibitory potency of 2-azetidinone cholesterol absorp-
tion inhibitors on photoa⁄nity labeling of the 145 kDa
protein correlated with their in vivo potency and as their
potency to inhibit binding of radiolabeled C-2 to rabbit
small intestinal BBMV.
3. Inhibition of labeling of the 145 kDa protein was speci¢c
for cholesterol absorption inhibitors. None of the sub-
strates for the intestinal transporters for bile acids, glucose,
alanine, L-lactam antibiotics/oligopeptides or long-chain
fatty acids exerted any e¡ect.
4. The extent of labeling of the 145 kDa protein was in-
creased in BBMV obtained from rabbits having received
a cholesterol-rich diet for 10 days.
These results strongly indicate that an integral membrane
protein of Mr 145 kDa in the brush border membrane of
rabbit small intestinal cells is responsible for the critical step
of intestinal cholesterol absorption, the transport across the
enterocyte brush border membrane. Whether this protein acts
as a solute transporter translocating monomeric cholesterol
across the enterocyte brush border membrane or is a receptor
triggering uptake by endocytosis or other mechanisms remains
to be elucidated.
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